Alcoa Corp (AA) Stock News

A class action lawsuit has been filed against Aardvark Therapeutics in the U.S. District Court for the Southern District of California. The lawsuit alleges that defendants made materially false and misleading statements in the company's IPO registration statement and throughout the class period (February 13, 2025 to May 14, 2026), specifically regarding the safety and commercial prospects of their drug ARD-101. Investors who purchased shares during this period can apply to be lead plaintiff by October 13, 2026.

Hagens Berman announces a securities class action lawsuit against Aardvark Therapeutics for allegedly making materially false statements about ARD-101's safety. The company failed to disclose cardiac observations during trials, leading to a voluntary pause of the Phase 3 HERO trial in February 2026 (56% stock decline) and an FDA clinical hold in May 2026 (32.1% additional decline). Investors with substantial losses have until October 13, 2026, to become lead plaintiffs.

Rosen Law Firm announces a securities class action lawsuit against Aardvark Therapeutics, Inc. for allegedly making materially false and misleading statements regarding the safety and prospects of its drug ARD-101. Investors who purchased securities during the IPO on February 13, 2025 or between February 13, 2025 and May 14, 2026 may be eligible to join the class action. The deadline to serve as lead plaintiff is October 13, 2026.

Apple shares have gained 24% YTD, outperforming major tech peers, driven by strong iPhone demand, the new foldable iPhone Duo, and 12% Services revenue growth. However, the stock's 35.18X forward P/E ratio is significantly higher than sector and peer averages, coupled with rising memory costs and supply constraints, warranting a cautious hold strategy despite solid long-term prospects.

Advance Auto Parts (AAP) has demonstrated a strong track record of beating earnings estimates, with an average surprise of 62.30% over the past two quarters. The company currently has a positive Earnings ESP of +2.73% combined with a Zacks Rank #3 (Hold), suggesting a high probability of another earnings beat in its upcoming report.

Grabar Law Office is investigating securities fraud and fiduciary duty breach claims against four companies: Aardvark Therapeutics for allegedly misrepresenting the safety profile of its drug candidate ARD-101 before a clinical hold was placed; Coastal Financial Corporation for failing to disclose deterioration in its CCBX partner loan portfolio and credit losses; Erasca, Inc. for making misleading statements about its ERAS-0015 therapy and improper comparisons to competitors; and New Era Energy & Digital for overstating progress on its data center project and allegedly engaging in fraudulent oil-and-gas schemes.

Archer Aviation is developing Hawthorne Municipal Airport near Los Angeles as an operational hub for its air-taxi network and innovation center for AI-powered aviation technologies. The company plans airport and hangar redevelopment to support its urban air mobility strategy, joining competitors like Joby Aviation and Eve Holding in building dedicated infrastructure for advanced air mobility operations.

Oculis announced that CEO Riad Sherif will present Licaminlimab, a novel topical anti-TNFα candidate for TNFR1-mediated dry eye disease, at Eyecelerator @ AAO 2026 on October 8. The company's PREDICT-1 registrational trial is on track for topline readout around year-end. Oculis will also sponsor the Neuro-Ophthalmology Subspecialty Day, highlighting its commitment to advancing neuro-ophthalmology research and innovation.

Pan American Silver (PAAS) rose 1.32% to $45.92, outperforming the S&P 500's 0.58% gain. Despite a 11.73% monthly decline, analysts expect strong earnings growth of 91.67% year-over-year with revenue projected at $1.24 billion (+44.54% YoY). The stock holds a Zacks Rank #3 (Hold) with a Forward P/E of 11.89, in line with industry averages. However, the Mining-Silver industry ranks in the bottom 14% of all industries.

American Airlines (AAL) closed at $13.00, up 1.33% in the latest session. The stock has declined 2.28% over the past month. The company is scheduled to report earnings on October 22, 2026, with projections showing a loss of $0.31 per share (down 82.35% year-over-year) despite revenue expected to reach $16.12 billion (up 17.74%). American Airlines currently holds a Zacks Rank of #3 (Hold), while the Transportation-Airline industry ranks 233rd out of 250+ industries.

Rosen Law Firm announces a securities class action lawsuit against Aardvark Therapeutics, with an October 13, 2026 deadline for investors to serve as lead plaintiff. The lawsuit alleges that defendants made materially false and misleading statements regarding the safety and prospects of their drug candidate ARD-101, causing investor damages when the true details emerged.

Remittix has opened its PayFi platform to 1,000 selected RTX token holders for real-user testing of crypto-to-bank payments ahead of its November 24, 2026 launch. The platform supports EUR and USD conversions across multiple blockchain networks. Meanwhile, Cardano trades near $0.24 with long-term bull case potential, and Aave V4 surpassed $1 billion in deposits, demonstrating strong adoption of practical crypto financial services.

Rosen Law Firm has announced multiple securities class action lawsuits against Aardvark Therapeutics, FuelCell Energy, and XTI Aerospace. The primary case involves Aardvark Therapeutics, where investors claim the company made materially false statements about the safety and prospects of its ARD-101 drug candidate in its IPO registration statement and throughout the class period. Investors have until October 13, 2026 to become lead plaintiffs in the Aardvark case.

American Airlines stock fell 1.73% on September 30, 2026, underperforming the S&P 500's 0.25% decline. The airline is projected to report negative earnings of -$0.31 per share with an 82.35% year-over-year decline, though revenue is expected to grow 17.74%. The Zacks Consensus EPS estimate has declined 60.4% over the past month, and the stock holds a Zacks Rank of #3 (Hold). The Transportation-Airline industry ranks in the bottom 6% of all industries.

Alphabet reported 15% year-over-year growth in Google Services revenues to $94.5 billion in Q2 2026, driven by strong performance in Search, YouTube, and subscriptions. AI integration, including AI Mode surpassing 1 billion monthly active users, is enhancing monetization and user engagement. The company faces competition from Meta Platforms and Apple, both leveraging AI-powered tools and expanding their service offerings.

argenx presented new clinical data at the AANEM and MGFA scientific sessions demonstrating deepening improvements in ocular myasthenia gravis (MG) with VYVGART, sustained one-year efficacy in anti-AChR antibody-negative MG patients, and benefits of earlier treatment initiation. Real-world evidence from over 1,100 U.S. MG patients showed greater clinical gains when treatment started within one year of diagnosis. Long-term CIDP data reinforced consistent safety and efficacy, with a Phase 4 study supporting direct transition from IVIg. Pipeline candidates empasiprubart and adimanebart showed promising Phase 2 results in multifocal motor neuropathy and congenital myasthenic syndrome respectively.

Pentagon awards RTX's Raytheon $20.7 billion contract for AMRAAM missiles amid stockpile concerns  Reuters

The FAA administrator said the Max 10 will be delayed until the agency can assess a software issue on the aircraft.

Rosen Law Firm is reminding investors in Aardvark Therapeutics, Inc. (AARD) of an October 13, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aardvark made materially false and misleading statements regarding the safety and prospects of its drug ARD-101, causing investor damages when the truth entered the market. The firm is also investigating claims related to Hyliion Holdings Corp. (HYLN) and FLOW cryptocurrency.

Ernest Rady, founder and Executive Chairman of American Assets Trust (AAT), purchased 50,000 shares worth approximately $1.1 million on September 14, 2026, at $21.65 per share. This marks his second major insider purchase in recent weeks, bringing his total beneficial stake to 24% of the REIT. The article interprets this insider buying as a bullish signal, noting that insiders typically only buy shares when they believe the stock price will rise, and studies show insider purchases often predict higher share prices within 30 days.

The iShares Gold Trust (IAU) and Goldman Sachs Physical Gold ETF (AAAU) offer nearly identical exposure to physical gold bullion with comparable performance. AAAU has a lower expense ratio of 0.18% versus IAU's 0.25%, while IAU offers significantly larger assets under management ($67.5 billion vs. $2.9 billion), providing better liquidity and scale for investors.

The 2026 NCAA Basketball Finals demonstrated strong commercial performance with record men's viewership (18.30 million average), 15-16% growth in women's championship audiences, sold-out Final Four tickets, and sustained sponsorship value from major corporate partners. Long-term sponsorship agreements and expanded international media rights, particularly Disney's $920 million women's basketball deal through 2032, underscore March Madness's position as a valuable sports property.

The Rosen Law Firm announced a securities class action lawsuit against Aardvark Therapeutics, Inc. (AARD) for allegedly making false and misleading statements regarding the safety profile of its drug ARD-101 and overstating its clinical, regulatory, and commercial prospects. The lawsuit covers investors who purchased securities between February 13, 2025 (IPO date) and May 14, 2026. The deadline to file a claim is October 13, 2026.

Pan American Silver (PAAS) declined 2.48% to $48.75, underperforming the broader market which gained significantly. The stock has fallen 5.8% over the past month. Despite strong earnings projections showing 91.67% EPS growth and 44.52% revenue growth for the upcoming quarter, the company holds a Zacks Rank #3 (Hold) rating with recent downward estimate revisions of 2.56%. The Mining - Silver industry ranks in the bottom 10% of all industries.

Aardvark Therapeutics faces a securities fraud class action lawsuit covering the period February 10, 2025 to May 14, 2026. The company voluntarily paused its Phase 3 HERO trial in February 2026 due to cardiac safety concerns, causing a 56.2% stock decline. In May 2026, the FDA placed a full clinical hold on the drug ARD-101, resulting in a further 32.1% stock drop. Investors who suffered losses are urged to file lead plaintiff motions by October 13, 2026.

EVE Energy showcased its Open Source Battery 4.0: AI Battery at IAA TRANSPORTATION 2026 in Hannover, featuring advanced LMX chemistry cells and intelligent battery management systems designed for commercial vehicles. The company secured strategic cooperation orders exceeding 30 GWh from major partners including BMZ, Janus Electric, Morris Commercial, Sunswap, and WEG, demonstrating strong market recognition for its electrification solutions.

Rosen Law Firm is reminding investors in Aardvark Therapeutics (AARD), UWM Holdings (UWMC), and ARS Pharmaceuticals (SPRY) of upcoming lead plaintiff deadlines in securities class action lawsuits. The lawsuits allege that defendants made materially false statements and failed to disclose material adverse facts about their businesses, with Aardvark specifically accused of overstating the safety and commercial prospects of its ARD-101 drug candidate.

Apple TV won 29 Emmys at the 78th Primetime Emmy Awards, with Apple Originals accumulating 917 total wins and 3,827 nominations. Apple's Services revenue grew 12% to a record $30.74 billion in the June quarter with a 75.6% gross margin. The company surpassed 1.5 billion paid subscriptions supported by over 2.5 billion active devices. However, Apple faces intense competition from Netflix and Disney in the streaming space.

Law firm Lowey Dannenberg is investigating Aardvark Therapeutics for potential federal securities violations related to its lead drug ARD-101. The company paused its Phase 3 trial in February 2026 due to cardiac safety concerns and faced an FDA clinical hold in May 2026, causing significant stock price declines and shareholder losses.

Apple (AAPL) closed at $337.30, up 1.47%, outperforming the S&P 500's 1.14% gain. The stock has gained 4.92% over the past month. Analysts project upcoming earnings of $1.99 per share (7.57% YoY growth) with revenue expected at $112.84 billion (10.12% growth). However, Apple carries a premium valuation with a Forward P/E of 37.43 versus the industry average of 21.45, and holds a Zacks Rank of #3 (Hold).